Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension

Hypertension

Volumn 57, Issue 3, 2011, Pages 413-420

  White, William B ^a,f   Weber, Michael A ^b   Sica, Domenic ^c   Bakris, George L ^d   Perez, Alfonso ^e   Cao, Charlie ^e   Kupfer, Stuart ^e  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e TAKEDA PHARMACEUTICALS   (United States)

^f UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

ambulatory blood pressure; angiotensin receptor blockers; azilsartan medoxomil; clinical trial; olmesartan; valsartan

Indexed keywords

AZILSARTAN MEDOXOMIL; OLMESARTAN; PLACEBO; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GROUPS BY AGE; HUMAN; HYPERKALEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; URINARY TRACT INFECTION;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; OXADIAZOLES; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 79953239152     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.163402     Document Type: Article

References (25)

1. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-1315. (Pubitemid 33016494)
2. Turnbull F, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomized trials. Lancet. 2003;362:1527-1535. (Pubitemid 37410190)
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High BP. Hypertension. 2003;42:1206-1252. (Pubitemid 37553153)
4. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension- European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1054.
5. Ruddy MC, Kostis JB. Angiotensin II receptor antagonists. In: Oparil S, Weber MA, eds. Hypertension. Philadelphia, PA: WB Saunders Co; 2000:621-637.
6. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled parallel-group trial. Clin Ther. 2001;23:833-850. (Pubitemid 32554566)
7. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomized trial against atenelol. Lancet. 2002;359:995-1003. (Pubitemid 34286536)
8. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:2049-2051. (Pubitemid 38781107)
9. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675. (Pubitemid 33126822)
10. Brenner BM, Cooper ME, deZeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
11. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
12. Azilsartan Medoxomil (TAK 491) Investigator's Brochure. 3rd ed. Deerfield, IL: Takeda Global Research & Development Center, Inc; 2007.
13. Smith HGD. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists. Am J Cardiovasc Drugs. 2007;7:347-356.
14. Ram CVS. Antihypertensive of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial design studies. Curr Med Res Opin. 2009;25:177-185.
15. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin Outcome Study. Hypertension. 2005;46:156-161. (Pubitemid 40946507)
16. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, De Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J, for the Systolic Hypertension in Europe Trial Investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA. 1999;282:539-546. (Pubitemid 29380290)
17. White WB. Advances in ambulatory blood pressure monitoring for the evaluation of antihypertensive therapy. In: White WB, ed. Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. 2nd ed. Totowa, NJ: Springer-Verlag-Humana Press; 2007:437-462.
18. Campbell P, Ghuman N, Wakefield D, Wolfson L, White WB. Long-term reproducibility of ambulatory blood pressure is superior to office blood pressure in the very elderly. J Hum Hypertens. 2010;24:749-754.
19. White WB. Relating cardiovascular risk to out-of-office blood pressure and the importance of controlling blood pressure 24 hours a day. Am J Med. 2008;121(suppl 8):S2-S7. (Pubitemid 351970085)
20. Neutel JM, Smith DH, Ram CV, Kaplan NM, Papademetriou V, Fagan TC, Lefkowitz MP, Kazempour MK, Weber MA. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med. 1993;94:181-187. (Pubitemid 23046444)
21. Smith DH, Cramer MJ, Neutel JM, Hettiarachchi R, Koval S. Comparison of telmisartan versus losartan: metanalysis of titration-to-response studies. Blood Press Monit. 2003;8:111-117. (Pubitemid 37034566)
22. Mansoor GA, White WB. Long-term reproducibility of ambulatory blood pressure. J Hypertens. 1994;12:703-708. (Pubitemid 24211290)
23. Mancia G, Omboni S, Parati G, Sega R, Trazzi S. Ambulatory blood pressure monitoring in the design of studies on antihypertensive drug efficacy. Am J Hypertens. 1993;6:233S-235S. (Pubitemid 23187090)
24. White WB, Cleveland JM, Rolleri RL. Utility of semi-automatic clinic and 24-hour ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril-Hydrochlorothiazide Hypertension Trial. J Hum Hypertens. 2008;22:559-568.
25. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment and control of hypertension, 1988-2008. JAMA. 2010;303:2043-2050.